Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This study tests a new drug called JSKN033 in 160 people with advanced non-small cell lung cancer that cannot be cured. The goal is to see if the drug is safe and shrinks tumors. The trial has two parts: first finding the best dose, then testing it in more patients.

This study tests a new drug called JSKN033 combined with standard chemotherapy, with or without another drug (bevacizumab), in people with advanced cervical cancer that has come back or spread. The goal is to see if the combination is safe and helps shrink or control tumors. Abou…

This study tests a new combination of two drugs (JSKN016 and D-0502) in people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard hormone therapy. About 60 adults will receive the drugs either every 2 or 3 weeks. The goal is…

This early-phase study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also watch for any signs that the drug shrinks…